Neovascular age-related macular degeneration
Clinical trials for Neovascular age-related macular degeneration explained in plain language.
Never miss a new study
Get alerted when new Neovascular age-related macular degeneration trials appear
Sign up with your email to follow new studies for Neovascular age-related macular degeneration, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Longer-Lasting eye injection could cut treatment visits for macular disease
Disease control Not yet recruitingThis study looks at whether switching to a higher-dose eye injection called aflibercept 8 mg can allow people with neovascular age-related macular degeneration (nAMD) or diabetic macular oedema (DME) to go longer between treatments. It follows adults in Portugal who have already …
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Sponsor: Grupo de Estudos da Retina • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Eye drops could replace needle injections for wet AMD
Disease control Not yet recruitingThis Phase 2a trial tests SCAI-005 eye drops in 50 adults with wet age-related macular degeneration (AMD). Participants will receive either a low dose, high dose, or placebo drops three times daily. The study aims to see if the drops can reduce retinal swelling and control the di…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase 2 • Sponsor: SCAI Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Could herbal pills cut eye injections for wet AMD? new trial launches
Disease control Not yet recruitingThis phase 3 trial tests whether adding Sanhuang Jingshiming Pills (a traditional Chinese herbal medicine) to standard ranibizumab injections can reduce the number of injections needed for wet age-related macular degeneration. About 450 adults aged 50-85 with active wet AMD will …
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase 3 • Sponsor: Tasly Pharmaceutical Group Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
The 20-Minute squeeze: how eye injections push pressure up
Knowledge-focused Not yet recruitingAnti-VEGF injections treat conditions like diabetic macular edema, age-related macular degeneration, and retinal vein occlusion by adding fluid inside the eye, which can briefly raise eye pressure. This observational study at Assiut University follows 50 adults receiving these ro…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Could years of eye injections weigh down the upper eyelid?
Knowledge-focused Not yet recruitingDoctors use anti-VEGF injections to treat retinal diseases such as age-related macular degeneration and diabetic macular edema, and patients often need these shots for years. During each injection, a small tool holds the eyelids open, stretching the upper lid. Researchers want to…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Sponsor: Abdulkadir Küçük • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC